RA Capital buys 548,580 Artiva shares at $7.91
Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions.
Rhea-AI Filing Summary
Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions. Entities managed by RA Capital purchased a total of 1,027,722 Artiva shares between June 9 and June 11, 2026 at prices around $6.91–$7.91 per share.
After these indirect purchases through RA Capital-managed vehicles, the reporting group is shown holding 16,231,717 shares of Artiva common stock. Footnotes state the adviser and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 548,580 | $7.91 | $4.34M |
| Purchase | Common Stock | 103 | $7.00 | $721.00 |
| Purchase | Common Stock | 479,039 | $6.91 | $3.31M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (7)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.77 to $7.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F3. Held directly by the Fund.
- F4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.605 to $8.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F5. Held directly by the Nexus Fund.
- F6. Held directly by Nexus Fund III.
- F7. Held directly by the Account.
Key Figures
Key Terms
weighted average price financial
indirect financial
beneficial ownership financial
pecuniary interest financial
separately managed account financial
AI-generated analysis. How Rhea-AI works. Not financial advice.